Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$129.86MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Todd Franklin Watanabe
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 354
- Beta
- 1.58
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 5.50
Financials
Revenue
$129.86M+17811.9%Net Income
$15.01MEBITDA
$17.15M+3429700.0%Free Cash Flow
$12.48MEPS (diluted)
$0.11Shares Outstanding (diluted)
135.90M+12769.1%Operating Expenses
$102.49MCash & Debt
$238.55MRevenue by Segment (annual)
$59.61MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $376.07M | $-16.14M | $-0.13 |
| 2024 | $196.54M | $-140.04M | $-1.16 |
| 2023 | $59.61M | $-262.14M | $-3.78 |
| 2022 | $3.69M | $-311.46M | $-5.66 |
| 2021 | $0.00 | $-206.36M | $-4.17 |
| 2020 | $0.00 | $-135.68M | $-3.80 |
| 2019 | $0.00 | $-42.00M | $-1.10 |
| 2018 | $0.00 | $-19.25M | $-0.53 |
| 2017 | $0.00 | $-4.98M | $-4.71 |
Valuation
ARQThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+11.11%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·1d ago·Neutral
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to
View source ↗ - Newsglobenewswire.com·4d ago·Positive
…ns combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with the 2026 “Best Prescription Skin Solution” Award by Marie Claire magazine.
View source ↗ - Newszacks.com·23d ago·Neutral
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last? Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·43d ago·Positive
Here's Why You Should Add ARQT Stock to Your Portfolio Now Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
View source ↗ - Newszacks.com·45d ago·Negative
5 Biotech Stocks Worth Adding to Your Portfolio Now New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
View source ↗
Earnings
Tue, Oct 27(in 2 weeks)
Consensus estimate $0.18 per share
Typical surprise +67.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.11 vs $0.06beat
- Wed, May 6$-0.09 vs $-0.02miss
- Wed, Feb 25$0.13 vs $0.03beat
- Tue, Oct 28$0.06 vs $-0.10beat
- Wed, Aug 6$-0.13 vs $-0.18beat
- Tue, May 6$-0.20 vs $-0.21beat
Estimates and results for ARQT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARQT officers and directors.
- Bought
- —
- Sold
- $5.6m
0 trades
35 trades
- Matsuda Masarusold
- Welgus Howard G.sold
- Matsuda Masarusold
- Curran Terriesold
- Curran Terriesold
- Burnett Patricksold
- Welgus Howard G.sold
- Burnett Patricksold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (11d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 12, 2026 (32d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 19, 2023 (32d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 22, 2022 (37d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.